Highlights
• GlaxoSmithKline (GSK) Australia extends its services agreement with MedAdvisor for a further 12 months
• GSK will continue utilising MedAdvisor’s medication management platform to to provide relevant information for patients prescribed three medicines within GSK Australia’s respiratory portfolio.
• Agreement will generate Patient Engagement Program (PEP), formerly known as Medication Training and Adherence Campaigns (MTAC), revenue for MedAdvisor.
• Allows GSK Australia to leverage the MedAdvisor platform to support patients on the safe and effective use of these medicines.
- Forums
- ASX - By Stock
- MDR
- Ann: GlaxoSmithKline Extends Service Agreement with MedAdvisor-MDR.AX
Ann: GlaxoSmithKline Extends Service Agreement with MedAdvisor-MDR.AX, page-2
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MDR (ASX) to my watchlist
|
|||||
Last
55.0¢ |
Change
-0.020(3.51%) |
Mkt cap ! $302.7M |
Open | High | Low | Value | Volume |
56.5¢ | 56.5¢ | 54.0¢ | $148.1K | 266.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6667 | 54.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
55.0¢ | 31685 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6667 | 0.540 |
1 | 9500 | 0.535 |
1 | 5000 | 0.520 |
2 | 9500 | 0.505 |
4 | 116001 | 0.500 |
Price($) | Vol. | No. |
---|---|---|
0.550 | 31685 | 1 |
0.555 | 1800 | 1 |
0.565 | 2500 | 1 |
0.570 | 237716 | 4 |
0.575 | 15221 | 1 |
Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
Featured News
MDR (ASX) Chart |